Effect of Ertugliflozin on Cardiac Function in Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 102 participants.
Also called NCT03717194
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 102 participants
- Sponsor
- Soo Lim
- Registry
-
NCT03717194
-
- Other papers using this trial's data
- Effect of ertugliflozin on left ventricular function in type 2 diabetes and pre-heart failure: the Ertu-GLS randomized clinical trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT03717194. Randomized; quadruple masking; primary purpose treatment. Start 2019-06-01 (actual); primary completion 2022-12-31 (actual). Results posted on 2024-11-20.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect of Ertugliflozin on Cardiac Function in Diabetes
- Acronym
- ERTU-GLS
- Condition
- Type2 Diabetes
- Condition
- Heart Failure
- Intervention (Drug)
- Ertugliflozin
- Intervention (Drug)
- Placebo
- Lead sponsor
- Soo Lim
- Collaborator
- MSD Korea Ltd.
Record details
- Record id
cardio:ct-nct03717194- Content hash
f96cce059d59d85ec1b6e5d625c524885a7fb7ede1dc3fdacf5a8f2f64d1fd29